Oncology Peer Review On-The-Go: Matthew Allaway, DO, on Transperineal Biopsy Approach for Prostate Cancer
Matthew Allaway, DO, spoke with CancerNetwork® about a new transperineal biopsy approach to detect cancer in hard-to-reach areas of the prostate.
CancerNetwork® spoke with Matthew Allaway, DO, founder and chief executive officer at Perineologic, about a new prostate cancer biopsy technique that uses a transperineal approach to detect cancer in harder to reach areas of the prostate.
Allaway touched on the American Cancer Society’s annual report, “Cancer Facts & Figures 2022,” which indicated the rate of advanced-stage prostate cancer cases have increased in recent years. He also detailed a companion study to the report, and walked through the specific details and benefits of this biopsy technique.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
Reference
Cancer Facts & Figures 2022. American Cancer Society. 2022. Accessed January 28, 2022. https://tinyurl.com/5rdc6nbc
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
